CTLA4 and neoplasm: However, the addition of anti-PD-1 and anti-CTLA-4 antibodies to shIDO-ST treatment (shIDO-ST + ICB) resulted in significant tumor control compared to shScr-ST + IgG or shIDO-ST + IgG as well as shScr-ST + ICB.